ASAHI KASEI THERAPEUTICS ANNOUNCES FDA APPROVAL OF HOVILPRI® (PRITELIVIR) TABLETS FOR MUCOCUTANEOUS HSV LESIONS REFRACTORY (WITH OR WITHOUT RESISTANCE) TO STANDARD ANTIVIRAL TREATMENT IN IMMUNOCOMPROMISED ADULTS

Reuters · 1d ago

Please log in to view news